Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium stibogluconate + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Vioquest Pharmaceuticals
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Sodium stibogluconate + interferon alfa-2b is a combination therapy comprising a small molecule phosphatase inhibitor and a recombinant cytokine. Sodium stibogluconate (SSG) acts as a potent inhibitor of protein tyrosine phosphatases, specifically SHP-1 and SHP-2, which are known to negatively regulate signaling pathways involved in immune cell activation and cytokine response. By inhibiting these phosphatases, SSG is intended to potentiate the anti-tumor and immunomodulatory effects of interferon alfa-2b. This combination was developed by the Cleveland Clinic and has been evaluated in Phase I clinical trials for the treatment of advanced solid tumors, lymphoma, and multiple myeloma.
- Brand names
- Lenocta
- Other names
- SSG + interferonSSG + IFN-alpha-2bSodium stibogluconate and interferon alfa-2b
02
Targets
PTPN6 (Protein tyrosine phosphatase non-receptor type 6)IFNAR (Immune system modulation via type I interferon receptor)PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)
Beyond the preview
Go deeper on sodium stibogluconate + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium stibogluconate + interferon alfa-2b.